Hep C trial for Biotron
Thursday, 07 August, 2008
Biotron [ASX: BIT] has started Phase Ib/IIa clinical trials of its BIT225 hepatitis C candidate.
The study will enlist 18 hep C positive patients, who will be sorted into two dosage groups and a placebo control group.
The trial is primarily a safety and tolerability study, but determining the pharmacokinetics and effectiveness of the drug are secondary objectives of the trial.
Biotron expects to conclude the trial by the end of the year.
BIT225 targets the p7 protein of HCV, and has demonstrated good antiviral activity in surrogate models of HCV infection. This trial follows on from a successful Phase I trail conducted in healthy volunteers.
Biotron began as the commercialisation arm of the John Curtin School of Medical Research at ANU.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
